Expert opinion on drug delivery最新文献_第5页

A breath of fresh air: inhaled antibodies to combat respiratory infectious diseases - a clinical trial overview. 呼吸新鲜空气：吸入抗体对抗呼吸道传染病-临床试验概述。

Expert opinion on drug delivery Pub Date : 2025-02-01 Epub Date: 2024-12-26 DOI: 10.1080/17425247.2024.2446608

Noémie Alphonse, Thomas Sécher, Nathalie Heuzé-Vourc'h

{"title":"A breath of fresh air: inhaled antibodies to combat respiratory infectious diseases - a clinical trial overview.","authors":"Noémie Alphonse, Thomas Sécher, Nathalie Heuzé-Vourc'h","doi":"10.1080/17425247.2024.2446608","DOIUrl":"10.1080/17425247.2024.2446608","url":null,"abstract":"Introduction: With the worldwide growing burden of respiratory tract infections (RTIs), innovative therapeutic approaches are in high demand. Inhaled antibodies (Abs) represent a promising avenue, offering targeted treatment options with potentially better therapeutic index compared to traditional delivery methods.Areas covered: This comprehensive review summarizes the challenges faced in delivering Abs by (intranasal and pulmonary) inhalation. It outlines the physiological and biological barriers encountered by inhaled drugs, as well as the influence of delivery devices and formulation on the deposition and efficacy of inhaled molecules. Moreover, it provides a detailed overview of the current clinical trial landscape of inhaled anti-RTI Abs, highlighting the progress in the development of inhaled Abs targeting a range of pathogens, such as severe acute respiratory syndrome coronavirus 2 and respiratory syncytial virus. The mechanism of action, therapeutic targets, and clinical outcomes of these novel therapies are detailed.Expert opinion: Delivery of Abs by inhalation faces several challenges. Addressing these challenges and developing specific approaches to deliver inhaled Abs represent a promising avenue for the development of the next generation of inhaled Abs. By offering targeted, localized therapy with the potential for a better therapeutic index, inhaled Abs could significantly improve outcomes for patients with RTIs.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"197-218"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bacterial and bacterial derivatives-based drug delivery systems: a novel approach for treating central nervous system disorders. 基于细菌和细菌衍生物的药物传递系统：治疗中枢神经系统疾病的新方法。

Expert opinion on drug delivery Pub Date : 2025-02-01 Epub Date: 2024-12-22 DOI: 10.1080/17425247.2024.2444364

Shizhu Gao, Xin Li, Bing Han

{"title":"Bacterial and bacterial derivatives-based drug delivery systems: a novel approach for treating central nervous system disorders.","authors":"Shizhu Gao, Xin Li, Bing Han","doi":"10.1080/17425247.2024.2444364","DOIUrl":"10.1080/17425247.2024.2444364","url":null,"abstract":"Introduction: Bacteria and their derivatives show great potential as drug delivery systems due to their unique chemotaxis, biocompatibility, and targeting abilities. In CNS disease treatment, bacterial carriers can cross the blood-brain barrier (BBB) and deliver drugs precisely, overcoming limitations of traditional methods. Advances in genetic engineering, synthetic biology, and nanotechnology have transformed these systems into multifunctional platforms for personalized CNS treatment.Areas covered: This review examines the latest research on bacterial carriers for treating ischemic brain injury, neurodegenerative diseases, and gliomas. Bacteria efficiently cross the blood-brain barrier via active targeting, endocytosis, paracellular transport, and the nose-to-brain route for precise drug delivery. Various bacterial drug delivery systems, such as OMVs and bacterial ghosts, are explored for their design and application. Databases were searched in Google Scholar for the period up to December 2024.Expert opinion: Future developments in bacterial drug delivery will rely on AI-driven design and high-throughput engineering, enhancing treatment precision. Personalized medicine will further optimize bacterial carriers for individual patients, but challenges such as biosafety, immune rejection, and scalability must be addressed. As multimodal diagnostic and therapeutic strategies advance, bacterial carriers are expected to play a central role in CNS disease treatment, offering novel precision medicine solutions.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"163-180"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fungal quorum sensing molecules as potential drugs in the treatment of chronic wounds and their delivery. 真菌群体感应分子作为治疗慢性伤口的潜在药物及其递送。

Expert opinion on drug delivery Pub Date : 2025-02-01 Epub Date: 2025-01-15 DOI: 10.1080/17425247.2025.2452303

Ilker S Bayer

{"title":"Fungal quorum sensing molecules as potential drugs in the treatment of chronic wounds and their delivery.","authors":"Ilker S Bayer","doi":"10.1080/17425247.2025.2452303","DOIUrl":"10.1080/17425247.2025.2452303","url":null,"abstract":"Introduction: Chronic non-healing wounds have emerged as a significant global healthcare challenge. Biofilm induced wound infections has been widely acknowledged. Despite the advanced understanding of biofilm formation, the existing approaches for diagnosing biofilms in wounds remain considerably suboptimal. Chemical signals produced by fungi to sense their environment, known as quorum sensing (QS) molecules are anticipated to cause revolution in non-healing wound antisepsis.Areas covered: Biofilms render chronic wounds resistant to treatment and impede tissue repair by inducing chronic inflammation. QS is a biochemical signaling pathway that involves certain secreted molecules, namely phenylethanoids, indolyl, and sesquiterpene alcohols that can significantly minimize and obliterate bacterial biofilms if properly applied and released in wound treatments.Expert opinion: QS molecules (QSMs) possess inhibitory properties that obstruct the formation of microbial biofilms and exhibit synergism with common antimicrobials. They can disrupt biofilms formed by drug-resistant microorganisms. The understanding of the current mechanisms and advancements in the utilization of QSMs within diverse drug delivery systems, and their release dynamics will be crucial in new drug design and delivery. Exploration of co-delivery of drugs alongside QS molecules, and assessing their impact on healing of chronic wounds before moving to clinical trials remain unaddressed.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"277-296"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Roadmap to discovery and early development of an mRNA loaded LNP formulation for liver therapeutic genome editing. 用于肝脏治疗性基因组编辑的mRNA负载LNP配方的发现和早期开发路线图。

Expert opinion on drug delivery Pub Date : 2025-02-01 Epub Date: 2025-02-15 DOI: 10.1080/17425247.2025.2452295

Annette Bak, Liping Zhou, Joanna Rejman, Marianna Yanez Arteta, Gunilla Nilsson, Marianne Ashford

{"title":"Roadmap to discovery and early development of an mRNA loaded LNP formulation for liver therapeutic genome editing.","authors":"Annette Bak, Liping Zhou, Joanna Rejman, Marianna Yanez Arteta, Gunilla Nilsson, Marianne Ashford","doi":"10.1080/17425247.2025.2452295","DOIUrl":"10.1080/17425247.2025.2452295","url":null,"abstract":"Introduction: mRNA therapeutics were a niche area in drug development before COVID vaccines. They are now used in vaccine development, for non-viral therapeutic genome editing, in vivo chimeric antigen receptor T (CAR T) cell therapies and protein replacement. mRNA is large, charged, and easily degraded by nucleases. It cannot get into cells, escape the endosome, and be translated to a disease-modifying protein without a delivery system such as lipid nanoparticles (LNPs).Areas covered: This article covers how to design, select, and develop an LNP for therapeutic genome editing in the liver. The roadmap is divided into selecting the right LNP for discovery via a design, make, test, and analyze cycle (DMTA). The design elements are focused on ionizable lipids in a 4-component LNP, and insights are provided for how to set an in vitro and in vivo testing strategy. The second section focuses on transforming the LNP into a clinical drug product and covers formulation, analytical development, and process optimization, with brief notes on supply and regulator strategies.Expert opinion: The perspective discusses the impact that academic-industry collaborations can have on developing new medicines for therapeutic genome editing in the liver. From the cited collaborations an enhanced understanding of intracellular trafficking, notably endosomal escape, and the internal structure of LNPs were attained and are deemed key to designing effective and safe LNPs. The knowledge gained will also enable additional assays and structural activity relationships, which would lead to the design of the next-generation delivery systems for nucleic acid therapies.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"239-254"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142967626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How can we advance drug delivery options using extracellular vesicles for pregnant women to reduce preterm birth? 我们如何利用细胞外囊泡为孕妇提供药物以减少早产？

Expert opinion on drug delivery Pub Date : 2025-02-01 Epub Date: 2025-01-06 DOI: 10.1080/17425247.2025.2449955

Ramkumar Menon, Lauren S Richardson, Ananth Kumar Kammala

引用次数: 0

Challenges and considerations in liposomal hydrogels for the treatment of infection. 脂质体水凝胶治疗感染的挑战和考虑。

Expert opinion on drug delivery Pub Date : 2025-02-01 Epub Date: 2025-01-10 DOI: 10.1080/17425247.2025.2451620

Željka Vanić, May Wenche Jøraholmen, Nataša Škalko-Basnet

{"title":"Challenges and considerations in liposomal hydrogels for the treatment of infection.","authors":"Željka Vanić, May Wenche Jøraholmen, Nataša Škalko-Basnet","doi":"10.1080/17425247.2025.2451620","DOIUrl":"10.1080/17425247.2025.2451620","url":null,"abstract":"Introduction: Liposomal hydrogels are novel drug delivery systems that comprise preformed liposomes incorporated in hydrogels destined for mostly localized drug therapy, herewith antimicrobial therapy. The formulation benefits from versatility of liposomes as lipid-based nanocarriers that enable delivery of various antimicrobials of different lipophilicities, and secondary vehicle, hydrogel, that assures better retention time of formulation at the infection site. Especially in an era of alarming antimicrobial resistance, efficient localized antimicrobial therapy that avoids systemic exposure of antimicrobial and related side effects is crucial.Areas covered: We provide an overview of liposomal hydrogels that were developed for superior delivery of antimicrobials at different infections sites, with focus on skin and vaginal infections. The review summarizes the challenges of infection site and most common infection-causing pathogens and offers commentary on most relevant features the formulation needs to optimize to increase the therapy outcome. We discuss the impact of liposomal composition, size, and choice of polymer-forming hydrogel on antimicrobial outcome based on the literature overview and own experience in the field.Expert opinion: Liposomal hydrogels offer improved therapy outcome in localized antimicrobial therapy. By fine-tuning of liposomal as well as hydrogel properties, formulations with superior performance can be optimized targeting specific infection site.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"255-276"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142967623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The pursuit of linear dosage in pharmacy: reservoir-based drug delivery systems from macro to micro scale. 药剂学对线性剂量的追求：从宏观到微观尺度的基于库的药物输送系统。

Expert opinion on drug delivery Pub Date : 2025-02-01 Epub Date: 2025-01-09 DOI: 10.1080/17425247.2024.2448026

Arkady S Abdurashtov, Pavel I Proshin, Gleb B Sukhorukov

{"title":"The pursuit of linear dosage in pharmacy: reservoir-based drug delivery systems from macro to micro scale.","authors":"Arkady S Abdurashtov, Pavel I Proshin, Gleb B Sukhorukov","doi":"10.1080/17425247.2024.2448026","DOIUrl":"10.1080/17425247.2024.2448026","url":null,"abstract":"Introduction: The pursuit of linear dosage in pharmacy is essential for achieving consistent therapeutic release and enhancing patient compliance. This review provides a comprehensive summary of zero-order drug delivery systems, with a particular focus on reservoir-based systems emanated from different microfabrication technologies.Areas covered: The consideration of recent advances in drug delivery systems is given to encompass the key areas including the importance of achieving a constant drug release rate for therapeutic applications. Detailed examination of reservoir-based systems, their design, mechanisms of action and materials used are highlighted. By addressing these areas, the discussion aims to provide a thorough understanding of most recent zero-order drug delivery systems, their performance advantages and methods of their manufacturing. To ensure the complete coverage of the explored research area, modern AI-assistant tools were used to find not only the most relevant, but also connected and similar articles.Expert opinion: Future developments in reservoir-based drug delivery systems are expected to significantly enhance therapeutic effectiveness and patient outcomes through the integration of innovative materials and technologies. The fabrication of intelligent drug delivery systems that utilize sensors and feedback mechanisms can enable real-time monitoring of drug release and patient reactions.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"219-238"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improving adherence by investigating the stability of dabigatran outside of the manufacturer's original packaging: a New Zealand perspective. 通过调查达比加群在制造商原始包装外的稳定性来改善依从性：新西兰的观点。

Expert opinion on drug delivery Pub Date : 2025-02-01 Epub Date: 2024-12-24 DOI: 10.1080/17425247.2024.2444359

Zainab Noori, Dale Griffiths, Stella Jung, Catherine Huang, Hiyori Nakano, Melody Wong, Jagdish K Jaiswal, Manisha Sharma

{"title":"Improving adherence by investigating the stability of dabigatran outside of the manufacturer's original packaging: a New Zealand perspective.","authors":"Zainab Noori, Dale Griffiths, Stella Jung, Catherine Huang, Hiyori Nakano, Melody Wong, Jagdish K Jaiswal, Manisha Sharma","doi":"10.1080/17425247.2024.2444359","DOIUrl":"10.1080/17425247.2024.2444359","url":null,"abstract":"Background: Dose administration aids (DAA) are widely used to improve adherence. In New Zealand (NZ) more pharmacies are utilizing automated filling robots to meet DAA demand. Pradaxa™ capsules containing dabigatran etexilate (DE) is problematic. It is moisture-sensitive, and Medsafe (NZ regulator), recommends keeping the capsule in its original packaging until administration. This prevents DE from repacking into DAA, reducing the effectiveness of the DAA. Overseas studies demonstrated stability of DE in DAA. However, the findings cannot be extrapolated to NZ environments.Research design and methods: Pradaxa™ 110 mg capsules repackaged in DAA were stored in conditions mimicking real-life settings (room temperature, bedroom and fridge) for 16 weeks. At predetermined timepoints, the capsules were evaluated for drug content and dissolution profile.Results: DE samples stored in NZ conditions for 16 weeks met the drug content requirement of 85-115% except for unit-dose sachet samples stored in fridge condition (79.7% ± 6.82). Samples demonstrated similarity in dissolution profile until 8 weeks with release rate decreased at 16 weeks under all storage conditions.Conclusion: DE capsules repackaged in DAA demonstrated stability for up to 8 weeks in all NZ storage conditions, confirming the safety of repackaging DE into a DAA.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"297-306"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chiral nanosystem and chiral supraparticles for drug delivery: an expert opinion. 用于给药的手性纳米系统和手性超颗粒：专家意见。

Expert opinion on drug delivery Pub Date : 2025-02-01 Epub Date: 2024-12-23 DOI: 10.1080/17425247.2024.2444347

Mahfoozur Rahman, Janhvi Singh, Alhussain Aodah, Majed Alrobaian, Nabil K Alruwaili, Waleed H Almalki, Salem Salman Almujri, Safia Obaidur Rab, Osama A Madkhali, Ankit Sahoo, Jonathan A Lal

{"title":"Chiral nanosystem and chiral supraparticles for drug delivery: an expert opinion.","authors":"Mahfoozur Rahman, Janhvi Singh, Alhussain Aodah, Majed Alrobaian, Nabil K Alruwaili, Waleed H Almalki, Salem Salman Almujri, Safia Obaidur Rab, Osama A Madkhali, Ankit Sahoo, Jonathan A Lal","doi":"10.1080/17425247.2024.2444347","DOIUrl":"10.1080/17425247.2024.2444347","url":null,"abstract":"Introduction: Chiral nanocarriers enhance therapeutic efficacy by improving in vivo stability and cellular uptake. Chemical functionalization reduces cytotoxicity, resulting in favorable biocompatibility. Nanoparticles self-assemble into supraparticles, enhancing drug delivery through improved retention and drug loading.Area covered: This review covers chiral nanostructures and chiral supraparticles, and their applications in drug delivery and various healthcare applications.Expert opinion: The chirality of biomaterials is crucial for advancing nanomedicine. Chiral nanosystem enhance drug delivery by interacting selectively with biological molecules, improving their specificity and efficacy. This reduces off-target effects and improves therapeutic outcomes. Research has focused on cellular uptake and elimination to ensure safety, and chiral nanomaterials also show promise in optical sensing and gene editing. Their biocompatibility and ability to self-assemble into supraparticles may make them ideal for drug delivery systems.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"143-162"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142840626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Versatility of emulgel in topical drug delivery transforming its expedition from bench to bedside. 多功能性凝胶在局部给药转变其远征从实验室到床边。

Expert opinion on drug delivery Pub Date : 2025-01-01 Epub Date: 2024-12-11 DOI: 10.1080/17425247.2024.2439457

Pragati Ramesh Kumbhar, Harita Desai, Vaibhavi Meghraj Desai, Sakshi Priya, Vikas Rana, Gautam Singhvi

{"title":"Versatility of emulgel in topical drug delivery transforming its expedition from bench to bedside.","authors":"Pragati Ramesh Kumbhar, Harita Desai, Vaibhavi Meghraj Desai, Sakshi Priya, Vikas Rana, Gautam Singhvi","doi":"10.1080/17425247.2024.2439457","DOIUrl":"10.1080/17425247.2024.2439457","url":null,"abstract":"Introduction: Emulgel is a novel formulation that improves drug's stability and topical administration by combining emulsion and gel matrix. Its special structure improves skin penetration and prolongs the release of therapeutic molecules. Emulgel is unique in the commercial market because of its therapeutic effects, convenience of usage, and versatility in both pharmaceutical and cosmetic uses. This report focuses on how it may improve user experience and transform topical treatments.Areas covered: This review explores the commercial applicability of emulgels as a topical delivery system. Industrially applicable composition and manufacturing strategies have been discussed along with characterization techniques. The market landscape, being the most critical aspect, has been thoroughly discussed with recent case studies, clinical trials, patents, and commercial formulations. The compiled findings in this review are adapted from reputed databases like Scopus, PubMed, Web of Science, NIH, ClinicalTrials.gov, Espacenet, and recent research articles published between years 2010-2024 that discussed the applications of emulgel.Expert opinion: Emulgels have gained commercialization potential because of their efficient drug delivery and patient-friendly qualities. However, navigating regulatory complexity is important because imprecise classifications may affect market access. Sustained innovation will be essential for overcoming these obstacles and improving chances in future.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"55-68"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142786981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0